Crossmark

What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?

Published Online: 2019-05-29

Published Print: 2020-09

Authors

Bellanger, Guillaume

Biotti, Damien

Patsoura, Sofia

Ciron, Jonathan

Ferrier, Marine

Gramada, Raluca

Meluchova, Zuzana

Lerebours, Fleur

Catalaa, Isabelle

Dumas, Hervé

Cognard, Christophe

Brassat, David

Bonneville, Fabrice
License Information

Text and Data Mining valid from 2019-05-29

Version of Record valid from 2019-05-29
More Information

Article History

Received: 19 November 2018

Accepted: 8 May 2019

First Online: 29 May 2019

Conflict of interest

: J. Ciron discloses the following relation: speaker at a meeting sponsored by Biogen in february 2019, with no relation with the topic of this article. C. Cognard discloses the following relation: consultant for Cerenovus, Stryker, Medtronic, Microvention, MIVI. D. Brassat discloses the following relations: grant received/grants pending: ARSEP, Medday, Biogen; consulting fees or honorarium: Biogen, Merck, Sanofi, Novartis, Roche, Teva, Chugai: support for travel to meetings for the study, manuscript preparation or other purposes: Biogen, Merck, Sanofi, Novartis, Roche, Teva; fees for participation in review activities such as data monitoring boards, etc: Chugai. G. Bellanger, D. Biotti, S. Patsoura, M. Ferrier, R. Gramada, Z. Meluchova, F. Lerebours, I. Catalaa, H. Dumas and F. Bonneville declare that they have no competing interests.

Document is current